Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
MONDAY, Sept. 12, 2022 -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for resectable stage II, III, or IV (M0) cutaneous squamous cell carcinoma had a pathological complete response, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Neoadjuvant Therapy | Pharmaceuticals | Skin Cancer | Squamous Cell Carcinoma | Study